Inbjudan till teckning av aktier

style="color: #fff !important;">
  Quarterly Report 1, January 2016

Dear Shareholders

We take great pleasure in reporting that Diamyd Medical continues to strengthen its position as a world leader in the development of Antigen Based Therapy for type 1 diabetes. A positive trend for the Diamyd® therapy could be reported from the end of the first 15-month period of the ongoing 30-month DIABGAD study. Limited six-month findings from the EDCR study will soon be available, as well as limited six-month findings from the DIAGNODE study.

Particularly pleasing is the growing interest shown by the pharmaceutical industry in our approach to combining GABA with antigen-based therapy for autoimmune diseases, not limited to type 1 diabetes, and for certain inflammatory disorders.

We take great pleasure in reporting that Diamyd Medical continues to strengthen its position as a world leader in the development of Antigen Based Therapy for type 1 diabetes.
Anders Essen-Möller, President and CEO

Annual Report

  November 05, 2015
 

A DEDICATED DIABETES COMPANY

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

The Share

The Diamyd Medical share is traded on NASDAQ Stockholm First North (ticker : DMYD B).

About First North

First North is an alternative marketplace operated by an exchange within the NASDAQ OMX group. Companies on First North are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on First North may therefore be higher than investing in a company on the main market. All companies with shares traded on First North have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at First North

Remium Nordic AB, Kungsgatan 12-14, 111 35 Stockholm, 08-454 32 00, www.remium.com

Calendar

Dates for financial information and other events
 February 08, 2016
Rights issue - Subscription period starts
 February 22, 2016
Rights issue – Subscription period ends
 April 06, 2016
Quarterly Report II
 June 29, 2016
Quarterly Report III
 October 12, 2016
Financial Statement

Holdings

NamePositionA SharesB SharesChangeDate
Anders Essen-Möller CEO and Board Member 958 584 3 654 431 + 25 000 2014-08-29
Maria-Teresa Essen-Möller Board Member 24 000 + 12 000 2013-07-10
Erik Nerpin Chairman of the Board 15 400 + 7 700 2013-07-10
Fredrik Åhlander Board Member
Anna Styrud Chief Financial Officer 30 000 + 9 000 2014-04-29
Erika Hillborg Senior Director Clinical Development 6 000 + 6 000 2013-05-20
Bertil Lindqvist Major Holder 2 757 855 - 22 898 2016-01-29
Johan Pharmanson Principal Auditor, BDO

Transaction history

NameChangeTypeDate
Bertil Lindqvist - 22 898 B Share 2016-01-29

Ten largest shareholders as of December 30, 2015

NameA SharesB SharesShare Capital (%)Votes (%)
Essen-Möller, Anders 958 584 3 653 255 20.85 43.06
Lindkvist, Bertil 2 780 753 12.57 9.04
Avanza Pension 2 211 462 10.00 7.19
Nordnet Pensionsförsäkring AB 672 409 3.04 2.19
Robur Försäkring 456 106 2.06 1.48
Protein Sciences Corporation 400 000 1.81 1.30
Försäkrings AB Skandia 235 289 1.06 0.77
Waldolf, Rolf Eric 224 000 1.01 0.73
Bohlin, Lennart 198 456 0.90 0.65
Relbo AB 188 332 0.85 0.61
Remaining shareholders 10 140 776 45.85 32.98
Total 958 584 21 160 838 100 % 100 %